PT  - JOURNAL ARTICLE
AU  - Lee, Iris K.
AU  - Jacome, Daniel A.
AU  - Cho, Joshua K.
AU  - Tu, Vincent
AU  - Young, Anthony
AU  - Dominguez, Tiffany
AU  - Northrup, Justin D.
AU  - Etersque, Jean M.
AU  - Lee, Hsiaoju
AU  - Ruff, Andrew
AU  - Aklilu, Ouniol
AU  - Bittinger, Kyle
AU  - Glaser, Laurel
AU  - Dorgan, Daniel
AU  - Hadjiliadis, Denis
AU  - Kohli, Rahul M.
AU  - Mach, Robert H.
AU  - Mankoff, David A.
AU  - Doot, Robert
AU  - Sellmyer, Mark A.
TI  - Imaging Sensitive and Drug-Resistant Bacterial Infection with [<sup>11</sup>C]-TMP: <em>In Vitro</em> and First-in-Human Evaluation
AID  - 10.1101/2021.09.21.21262899
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.21.21262899
4099  - http://medrxiv.org/content/early/2021/09/22/2021.09.21.21262899.short
4100  - http://medrxiv.org/content/early/2021/09/22/2021.09.21.21262899.full
AB  - Recently, several molecular imaging strategies have developed to image bacterial infections in humans. Nuclear approaches, specifically positron emission tomography (PET), affords sensitive detection and the ability to non-invasively locate infections deep within the body. Two key radiotracer classes have arisen: metabolic approaches targeting bacterial specific biochemical transformations, and antibiotic-based approaches that have inherent selectivity for bacteria over mammalian cells. A critical question for clinical application of antibiotic radiotracers is whether resistance to the template antibiotic abrogates specific uptake, thus diminishing the predictive value of the diagnostic test. We recently developed small-molecule PET radiotracers based on the antibiotic trimethoprim (TMP), including [11C]-TMP, and have shown their selectivity for imaging bacteria in preclinical models. Here, we measure the in vitro uptake of [11C]-TMP in pathogenic susceptible and drug-resistant bacterial strains. Both resistant and susceptible bacteria showed similar in vitro uptake, which led us to perform whole genome sequencing of these isolates to identify the mechanisms of TMP resistance that permit retained radiotracer binding. By interrogating these isolate genomes and a broad panel of previously sequenced strains, we reveal mechanisms where uptake or binding of TMP radiotracers can potentially be maintained despite the annotation of genes conferring antimicrobial resistance. Finally, we present several examples of patients with both TMP-sensitive and drug-resistant infections in our first-in-human experience with [11C]-TMP. This work underscores the ability of an antibiotic radiotracer to image bacterial infection in patients, which may allow insights into human bacterial pathogenesis, infection diagnosis, and antimicrobial response monitoring.One Sentence Summary The PET radiotracer [11C]-trimethoprim shows high uptake in both TMP-sensitive and -resistant bacteria in vitro, the potential for imaging many different pathogenic strains, and uptake in patients with active infections.Competing Interest StatementM.A.S. and R.H.M. have filed US patent US20180104365A1 assigned to the University of Pennsylvania on radiotracer derivatives of trimethoprim for medical imaging. M.A.S. and R.H.M. hold equity in Vellum Biosciences, a corporate entity which is commercializing TMP radiotracers.Clinical TrialNCT03424525Funding StatementThis research was supported by Institute for Translational Medicine and Therapeutics (ITMAT). M.A.S. is supported by the Burrough's Wellcome Fund Career Award for Medical Scientists and NIH Office of the Director Early Independence Award (DP5-OD26386). D.A.J. is supported by the NIH Pharmacological Sciences Predoctoral Research Training Program (NIHT32-GM008076).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UPENN IRB 3800 Spruce St., First Floor Suite 151 Philadelphia, PA 19104 215.573.2540All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, MAS, upon reasonable request.